The Federal Trade Commission (FTC) has intensified its focus on pharmaceutical manufacturers’ activities regarding the listing of patents in the Orange Book. This added scrutiny aims to curb improper or inaccurate patent listings that hinder market competition and delay the entry of generic drugs. Colin Kass and David Munkittrick at Proskauer delve into the implications of this regulatory move, questioning its effectiveness in facilitating the entry of generic pharmaceutical products.
To explore the broader context and detailed analysis by Kass and Munkittrick, you can read the article on Law360.